activated recombinant human factor VII, long acting

DRUG3 trials

Sponsors

Novo Nordisk A/S

Conditions

Congenital Bleeding DisorderHaemophilia AHaemophilia A With InhibitorsHaemophilia BHaemophilia B With InhibitorsHealthy

Phase 1

Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B

CompletedNCT00922792

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A, Haemophilia B

Start: 2009-06-30End: 2009-09-30Updated: 2016-05-13

A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers

CompletedNCT00951873

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A, Haemophilia B +1

Start: 2009-07-31End: 2010-04-30Updated: 2016-05-13

Phase 2

Safety and Efficacy of 3 Different Doses of Long Acting Factor VII in Haemophilia A or B Patients With Inhibitors

CompletedNCT00951405

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Start: 2009-09-01End: 2011-03-29Updated: 2018-09-05

Related Papers

40K glycoPEGylated, recombinant FVIIa: 3-month, double-blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors.

2013-07-0125 citations